Novo Historical Cash Flow
| NVO Stock | USD 106.80 0.67 0.63% |
Analysis of Novo Nordisk cash flow over time is an excellent tool to project Novo Nordisk AS future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 8.4 B or Depreciation of 9.9 B as it is a great indicator of Novo Nordisk ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Novo Nordisk AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novo Nordisk AS is a good buy for the upcoming year.
Novo |
About Novo Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Novo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Novo's non-liquid assets can be easily converted into cash.
Novo Nordisk Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Novo Nordisk AS to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Novo Nordisk operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Novo Nordisk AS financial statement analysis. It represents the amount of money remaining after all of Novo Nordisk AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Novo Nordisk's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Novo Nordisk's Total Cash From Operating Activities is very stable compared to the past year. As of the 1st of December 2024, Net Income is likely to grow to about 87.9 B, though Change To Inventory is likely to grow to (7.1 B).
Novo Nordisk cash flow statement Correlations
Click cells to compare fundamentals
Novo Nordisk Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novo Nordisk cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.3B) | (895M) | (1.1B) | (4.8B) | (7.4B) | (7.1B) | |
| Change In Cash | (218M) | (3.2B) | (1.5B) | 1.9B | 1.7B | 1.8B | |
| Stock Based Compensation | 363M | 823M | 1.0B | 1.5B | 2.1B | 2.3B | |
| Free Cash Flow | 35.6B | 29.9B | 47.6B | 64.1B | 70.0B | 73.5B | |
| Change In Working Capital | (3.4B) | (4.4B) | (8.7B) | (5.3B) | (12.2B) | (11.6B) | |
| Begin Period Cash Flow | 15.6B | 15.4B | 12.2B | 10.7B | 12.7B | 8.4B | |
| Other Cashflows From Financing Activities | (11.5B) | 5.7B | 22.2B | 11.2B | (43.9B) | (41.7B) | |
| Depreciation | 5.7B | 5.8B | 6.0B | 7.4B | 9.4B | 9.9B | |
| Other Non Cash Items | (4.4B) | (3.4B) | (2.5B) | 6.3B | 4.9B | 5.2B | |
| Capital Expenditures | 11.2B | 22.1B | 7.4B | 14.8B | 38.9B | 40.8B | |
| Total Cash From Operating Activities | 46.8B | 52.0B | 55B | 78.9B | 108.9B | 114.4B | |
| Net Income | 39.0B | 42.1B | 47.8B | 55.5B | 83.7B | 87.9B | |
| Total Cash From Financing Activities | (35.5B) | (32.2B) | (25.5B) | (51.8B) | (63.2B) | (60.0B) | |
| End Period Cash Flow | 15.4B | 12.2B | 10.7B | 12.7B | 14.4B | 8.9B | |
| Dividends Paid | 19.4B | 20.1B | 21.5B | 25.3B | 31.8B | 33.4B | |
| Sale Purchase Of Stock | (15.3B) | (16.9B) | (19.4B) | (24.1B) | (29.9B) | (28.4B) | |
| Change To Account Receivables | (2.1B) | (2.8B) | (12.9B) | (9.9B) | (14.2B) | (13.5B) | |
| Other Cashflows From Investing Activities | 20M | 18M | 4M | (10.2B) | (9.1B) | (8.7B) | |
| Change To Liabilities | (398M) | (641M) | 3.2B | 6.7B | 7.7B | 8.1B | |
| Investments | (11.5B) | (22.4B) | (5.9B) | (24.9B) | (43.9B) | (41.7B) | |
| Total Cashflows From Investing Activities | (11.5B) | (22.4B) | (31.6B) | (24.9B) | (22.4B) | (21.3B) | |
| Change To Operating Activities | 441M | 5M | 2.2B | 2.6B | 3.0B | 3.2B | |
| Change To Netincome | 6.8B | 8.9B | 10.6B | 22.1B | 25.5B | 26.7B | |
| Net Borrowings | (741M) | 4.7B | 15.5B | (2.4B) | (2.8B) | (2.6B) |
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.87 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.75 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | ANRO | Alto Neuroscience, | PairCorr |
Moving against Novo Stock
| 0.84 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.72 | FNMFO | Federal National Mortgage | PairCorr |
| 0.61 | KB | KB Financial Group | PairCorr |
| 0.5 | ITCL | Banco Ita Chile | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.